NASDAQ:NEPT

Neptune Wellness Solutions Competitors

$1.18
-0.09 (-7.09 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.17
Now: $1.18
$1.26
50-Day Range
$1.20
MA: $1.44
$1.70
52-Week Range
$1.15
Now: $1.18
$3.60
Volume1.51 million shs
Average Volume5.64 million shs
Market Capitalization$195.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43

Competitors

Neptune Wellness Solutions (NASDAQ:NEPT) Vs. ESPR, ORIC, HGEN, KPTI, LXRX, and ICPT

Should you be buying NEPT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Neptune Wellness Solutions, including Esperion Therapeutics (ESPR), ORIC Pharmaceuticals (ORIC), Humanigen (HGEN), Karyopharm Therapeutics (KPTI), Lexicon Pharmaceuticals (LXRX), and Intercept Pharmaceuticals (ICPT).

Neptune Wellness Solutions (NASDAQ:NEPT) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Neptune Wellness Solutions and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness Solutions-97.35%-46.39%-37.77%
Esperion Therapeutics-46.15%-629.88%-41.43%

Valuation & Earnings

This table compares Neptune Wellness Solutions and Esperion Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness Solutions$22.05 million8.86$-45,760,000.00($0.43)-2.74
Esperion Therapeutics$148.36 million5.23$-97,170,000.00($3.59)-7.67

Neptune Wellness Solutions has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Neptune Wellness Solutions has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are held by institutional investors. 7.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neptune Wellness Solutions and Esperion Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Esperion Therapeutics24312.30

Neptune Wellness Solutions presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Esperion Therapeutics has a consensus price target of $50.60, suggesting a potential upside of 83.73%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neptune Wellness Solutions is more favorable than Esperion Therapeutics.

Summary

Neptune Wellness Solutions beats Esperion Therapeutics on 10 of the 15 factors compared between the two stocks.

Neptune Wellness Solutions (NASDAQ:NEPT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Neptune Wellness Solutions and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness Solutions-97.35%-46.39%-37.77%
ORIC PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Neptune Wellness Solutions and ORIC Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness Solutions$22.05 million8.86$-45,760,000.00($0.43)-2.74
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

ORIC Pharmaceuticals has lower revenue, but higher earnings than Neptune Wellness Solutions.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are held by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neptune Wellness Solutions and ORIC Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
ORIC Pharmaceuticals01602.86

Neptune Wellness Solutions presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 107.97%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neptune Wellness Solutions is more favorable than ORIC Pharmaceuticals.

Summary

ORIC Pharmaceuticals beats Neptune Wellness Solutions on 5 of the 8 factors compared between the two stocks.

Neptune Wellness Solutions (NASDAQ:NEPT) and Humanigen (NASDAQ:HGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Neptune Wellness Solutions and Humanigen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness Solutions-97.35%-46.39%-37.77%
HumanigenN/A-302.90%-174.74%

Valuation & Earnings

This table compares Neptune Wellness Solutions and Humanigen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness Solutions$22.05 million8.86$-45,760,000.00($0.43)-2.74
HumanigenN/AN/A$-10,290,000.00N/AN/A

Humanigen has lower revenue, but higher earnings than Neptune Wellness Solutions.

Volatility and Risk

Neptune Wellness Solutions has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Humanigen has a beta of -0.79, indicating that its stock price is 179% less volatile than the S&P 500.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are held by institutional investors. Comparatively, 30.2% of Humanigen shares are held by institutional investors. 37.5% of Humanigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neptune Wellness Solutions and Humanigen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Humanigen01502.83

Neptune Wellness Solutions presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Humanigen has a consensus price target of $29.8333, suggesting a potential upside of 120.33%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neptune Wellness Solutions is more favorable than Humanigen.

Summary

Neptune Wellness Solutions beats Humanigen on 6 of the 11 factors compared between the two stocks.

Neptune Wellness Solutions (NASDAQ:NEPT) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Neptune Wellness Solutions and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness Solutions-97.35%-46.39%-37.77%
Karyopharm Therapeutics-221.23%-187.66%-56.42%

Valuation & Earnings

This table compares Neptune Wellness Solutions and Karyopharm Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness Solutions$22.05 million8.86$-45,760,000.00($0.43)-2.74
Karyopharm Therapeutics$40.89 million17.33$-199,590,000.00($3.22)-2.93

Neptune Wellness Solutions has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Neptune Wellness Solutions has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are held by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neptune Wellness Solutions and Karyopharm Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Karyopharm Therapeutics01802.89

Neptune Wellness Solutions presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Karyopharm Therapeutics has a consensus price target of $29.8750, suggesting a potential upside of 216.47%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neptune Wellness Solutions is more favorable than Karyopharm Therapeutics.

Summary

Neptune Wellness Solutions beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.

Neptune Wellness Solutions (NASDAQ:NEPT) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Neptune Wellness Solutions and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness Solutions-97.35%-46.39%-37.77%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Valuation & Earnings

This table compares Neptune Wellness Solutions and Lexicon Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness Solutions$22.05 million8.86$-45,760,000.00($0.43)-2.74
Lexicon Pharmaceuticals$322.07 million2.19$130.13 million$1.353.61

Lexicon Pharmaceuticals has higher revenue and earnings than Neptune Wellness Solutions. Neptune Wellness Solutions is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Neptune Wellness Solutions has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are held by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neptune Wellness Solutions and Lexicon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Lexicon Pharmaceuticals06202.25

Neptune Wellness Solutions presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Lexicon Pharmaceuticals has a consensus price target of $9.40, suggesting a potential upside of 92.62%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neptune Wellness Solutions is more favorable than Lexicon Pharmaceuticals.

Neptune Wellness Solutions (NASDAQ:NEPT) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neptune Wellness Solutions and Intercept Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Intercept Pharmaceuticals115802.29

Neptune Wellness Solutions presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Intercept Pharmaceuticals has a consensus price target of $50.6957, suggesting a potential upside of 143.73%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neptune Wellness Solutions is more favorable than Intercept Pharmaceuticals.

Volatility and Risk

Neptune Wellness Solutions has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Profitability

This table compares Neptune Wellness Solutions and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness Solutions-97.35%-46.39%-37.77%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Valuation & Earnings

This table compares Neptune Wellness Solutions and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness Solutions$22.05 million8.86$-45,760,000.00($0.43)-2.74
Intercept Pharmaceuticals$252 million2.74$-344,680,000.00($10.89)-1.91

Neptune Wellness Solutions has higher earnings, but lower revenue than Intercept Pharmaceuticals. Neptune Wellness Solutions is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Neptune Wellness Solutions beats Intercept Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Neptune Wellness Solutions Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.54-2.4%$775.42 million$148.36 million-7.15
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.02-0.1%$771.33 millionN/A0.00Increase in Short Interest
Humanigen logo
HGEN
Humanigen
1.7$13.54-2.6%$724.15 millionN/A0.00Analyst Report
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.44-2.2%$708.58 million$40.89 million-3.26News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-0.8%$704.45 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80-2.9%$689.77 million$252 million-2.13
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17-0.9%$682.20 million$150,000.00-4.53News Coverage
Chimerix logo
CMRX
Chimerix
1.3$7.91-1.8%$677.72 million$12.52 million-13.88
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.32-4.2%$677.00 million$13.80 million-14.16Analyst Report
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.55-6.8%$664.26 million$6.83 million-19.12
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.61-1.1%$662.95 million$2.22 million-15.35News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.83-3.1%$658.06 million$5.09 million-6.38
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.02-3.4%$649.75 million$19.56 million-18.72
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$13.42-44.4%$647.33 million$1.52 million-7.14High Trading Volume
Increase in Short Interest
News Coverage
Gap Up
Veru logo
VERU
Veru
1.4$8.88-2.4%$638.58 million$42.59 million-31.71Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.67-4.6%$621.67 million$17.26 million-4.08
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.20-2.1%$619.33 millionN/A-2.30Increase in Short Interest
News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.0%$603.93 million$59.29 million-23.67Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.51-4.4%$602.28 million$9.64 million-5.13
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.91-0.7%$599.59 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56-1.0%$598.75 millionN/A-9.87Analyst Report
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$592.69 million$143.01 million-1.08
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.58-5.3%$581.37 million$26.74 million18.94News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.67-0.5%$580.62 millionN/A-16.05
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.84-6.5%$578.15 millionN/A-4.35Analyst Upgrade
News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.61-2.1%$573.91 million$12.69 million-11.35Increase in Short Interest
News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$42.87-0.6%$566.61 million$195.89 million122.49
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.55-2.3%$546.63 million$1.19 million-6.90
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.86-0.6%$543.69 millionN/A-5.19
OrganiGram logo
OGI
OrganiGram
1.6$2.34-11.1%$543.51 million$64.61 million-3.44Analyst Downgrade
Decrease in Short Interest
Gap Down
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.84-1.0%$526.59 millionN/A-4.63News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.02-1.1%$523.94 millionN/A-8.54
89bio logo
ETNB
89bio
1.6$25.81-1.9%$517.10 millionN/A-5.11Insider Selling
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.96-4.5%$515.68 million$57.49 million-6.69News Coverage
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.61-1.0%$515.18 millionN/A-5.44
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.64-3.0%$513.23 millionN/A-8.13
Inventiva logo
IVA
Inventiva
0.0$13.27-0.9%$512.62 millionN/A0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-0.2%$509.61 million$25 million-18.52
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.85-1.2%$507.37 millionN/A-3.99
Akouos logo
AKUS
Akouos
1.6$14.60-2.4%$502.27 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$7.81-3.1%$494.96 millionN/A-5.24Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$16.48-1.7%$485.48 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50-1.9%$484.34 million$58.12 million-15.70Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.18-3.5%$478.24 million$59.22 million40.90
AC Immune logo
ACIU
AC Immune
1.3$6.51-0.0%$468.31 million$111.75 million-7.23Analyst Upgrade
Analyst Revision
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$465.22 million$17.46 million-1.92
Evolus logo
EOLS
Evolus
1.5$10.55-0.7%$461.38 million$34.92 million-5.20
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.17-0.9%$460.03 million$49.65 million-1.65
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.39-1.8%$455.79 million$102.31 million6.55Increase in Short Interest
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.